In a randomized trial conducted in 2020-2021 of patients with COVID-19 and severe hypoxemia, 12 mg of dexamethasone did not statistically significantly reduce the number of days patients were alive without life support at 28 days compared with 6 mg of dexamethasone.
In this video, Sheila Myatra, MD (Homi Bhabha National Institute, Mumbai, India), Balasubramanian Venkatesh, MD (The George Institute for Global Health, Sydney, Australia) and Anders Perner, MD, PhD (Rigshospitalet, Copenhagen, Denmark) present findings from the COVID STEROID 2 Trial at a Critical Care Reviews livestream presentation on October 21, 2021.
An oral editorial, author reply to the oral editorial, a Q&A session, and a panel discussion follow.
Click the related article link for full trial details.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.